New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 7, 2014
12:23 EDTTKPYY, FURXFuriex confirms Takeda's NDA submission for Trelagliptin Succinate in Japan
Furiex Pharmaceuticals (FURX) confirmed that Takeda Pharmaceutical Company Limited (TKPYY) announced that it has submitted a New Drug Application, or NDA, to the Japanese Ministry of Health, Labour and Welfare for trelagliptin succinate, a once weekly dosage treatment for type 2 diabetes. Under Furiex’s agreement with Takeda, Furiex is eligible to receive royalties and sales-based milestones if trelagliptin succinate is approved and marketed in Japan.
News For FURX;TKPYY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 4, 2015
07:26 EDTTKPYYWorldwide Business Research to hold a conference
BioNetwork East 2015 Partnering Conference is being held in Miami on May 4-6.
April 29, 2015
05:59 EDTTKPYYTakeda agrees to pay $2.4B to settle suits over cancer risk of Actos
Takeda Pharmaceutical and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., announced that they have reached an agreement expected to resolve the vast majority of ACTOS product liability lawsuits pending against Takeda in the U.S. Takeda will take a $2.7B charge against earnings in 4Q14 to cover the settlement and the costs associated with defending remaining cases and for other related litigation. The settlement will become effective if 95% of current litigants and claimants opt into the settlement. Once that threshold is achieved, Takeda will pay $2.37B into a settlement fund. However, that figure will rise to $2.4B if 97% or more of the current litigants and claimants opt to participate in the settlement.Takeda believes that the claims made in this litigation are without merit, and does not admit liability. Takeda believes the company acted responsibly with regard to ACTOS, and that ACTOS has a positive benefit/risk profile for the treatment of type 2 diabetes. Takeda’s decision to settle does not change the company’s continued commitment to ACTOS. ACTOS continues to be available as a treatment option in the U.S., Japan and other countries. Pioglitazone has been approved for use in 95 countries, including the U.S., Japan, several in Europe, Australia, Brazil, Canada and Russia, to highlight a few. The settlement will reduce financial uncertainties for the company and provides a significant degree of assurance toward resolving a high percentage of the ACTOS product liability claims. The settlement allows the company to fully focus on developing innovative medicines for patients around the world. Under the settlement, current litigants and claimants who meet prescribed criteria would receive payouts from the fund. The settlement will not affect Takeda's ability to pay dividends.
April 22, 2015
07:37 EDTTKPYYOrexigen and Takeda receive Paragraph IV certification notice
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use